Emergent Product Development UK Limited

Imperial College Innovations Limited

Microscience Limited

Pharmacia & Upjohn Company

Other

Smithkline Beecham Corporation

Vmax Ltd.

Rpms Technology Limited

David William Holden

Jacqueline Elizabeth Shea

Robert Graham Feldman

Gordon Dougan

Michael Hensel

Joseph David Santangelo

Zoe Hindle

Ji Min Mei

Enda Elizabeth Clarke

Michael Arthur Lonetto

David John Holmes

Karen Anne Ingraham

Alison Francis Chalker

Damien McDevitt

Paul Howard Everest

Jennifer E Ray

Andrea Marra

Gee W Lau

Sauli J Haataja

Liqing Zhou

Jun Yu

Helen Rachel Crooke

The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.

Attenuated salmonella SP12 mutants as antigen carriers

The present invention pertains to amicroorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing ainfection in a patient.

Attenuated microorganisms for the treatment of infection

A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of:

Identification of genes

[object Object]

A series of genes fromare shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.

Virulence genes, proteins, and their use

The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SP12 gene locus, wherein at least one gene of the SP12 locus is inactivated, wherein the inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is the attenuated gram-negative cell, wherein the cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for the antigen, wherein the cell is capable of expressing the nucleic acid molecule or capable of causing the expression of the nucleic acid molecule in a target cell.

The present invention is based on the identification of a series of virulence genes inK1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.

Virulence genes and proteins, and their use

The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.

virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and provision of novel mutants useful in vaccines.

Anti-bacterial methods and materials

virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel mutants useful in vaccines.

The invention provides tktA polypeptides and polynucleotides encoding tktA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tktA polypeptides and polynucleotides to screen for antibacterial compounds and for the detection of

Growing community of inventors

London, United Kingdom

David William Holden